← back to search

Fred G. Barker

Harvard University · US
Area of research
Epidemiology · Genetics
Research interest
Research interests include Meningioma and schwannoma management, Glioma Diagnosis and Treatment, Geological and Geochemical Analysis, and Neurofibromatosis and Schwannoma Cases.
h-index
88
citations
27,950
works
393
NIH funding
primary concept
email

Recent publications

Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma
Blood 2024cited by 26position: middledoi
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
New England Journal of Medicine 2023cited by 128position: middledoi
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
Neuro-Oncology Advances 2023cited by 22position: middledoi
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation
Genetics in Medicine 2022cited by 268position: middledoi
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis
JAMA Oncology 2022cited by 68position: middledoi
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
Genetics in Medicine 2021cited by 744position: middledoi
Effect of Ventral vs Dorsal Spinal Surgery on Patient-Reported Physical Functioning in Patients With Cervical Spondylotic Myelopathy
JAMA 2021cited by 178position: middledoi
A rapid genotyping panel for detection of primary central nervous system lymphoma
Blood 2021cited by 40position: middledoi
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery
Neuro-Oncology 2020cited by 34position: middledoi
Editorial. COVID-19 and neurosurgical practice: an interim report
Journal of neurosurgery 2020cited by 30position: middledoi
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Cancer 2019cited by 105position: middledoi
Genotype-targeted local therapy of glioma
Proceedings of the National Academy of Sciences 2018cited by 54position: middledoi
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
The Lancet Oncology 2017cited by 1,176position: middledoi
Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial
International Journal of Radiation Oncology*Biology*Physics 2017cited by 83position: middledoi
Launching Effectiveness Research to Guide Practice in Neurosurgery: A National Institute Neurological Disorders and Stroke Workshop Report
Neurosurgery 2017cited by 33position: middledoi
Laminectomy plus Fusion versus Laminectomy Alone for Lumbar Spondylolisthesis
New England Journal of Medicine 2016cited by 855position: middledoi
Natural history of cavernous malformation
Neurology 2016cited by 181position: middledoi
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials
Neurology 2016cited by 46position: middledoi
N107C/CEC.3: A Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
International Journal of Radiation Oncology*Biology*Physics 2016cited by 33position: middledoi
Current status and recommendations for biomarkers and biobanking in neurofibromatosis
Neurology 2016cited by 22position: middledoi
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
JNCI Journal of the National Cancer Institute 2015cited by 252position: lastdoi
Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade
Neuro-Oncology 2015cited by 131position: middledoi
Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes
Journal of neurosurgery 2015cited by 116position: middledoi
Rapid Intraoperative Molecular Characterization of Glioma
JAMA Oncology 2015cited by 90position: middledoi
Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database
Journal of Clinical Neuroscience 2014cited by 88position: middledoi
Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases: Table 1
Journal of Neurology Neurosurgery & Psychiatry 2013cited by 123position: middledoi
Hearing and facial function outcomes for neurofibromatosis 2 clinical trials
Neurology 2013cited by 43position: middledoi
Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
Otology & Neurotology 2012cited by 252position: lastdoi
Extracranial-Intracranial Bypass for Stroke—Is This the End of the Line or a Bump in the Road?
Neurosurgery 2012cited by 102position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Evanthia Galanis · Mayo Clinic4 papers (2017–2022)Xiomara W. Carrero · Wake Forest University4 papers (2016–2022)Jan C. Buckner · Mayo Clinic in Arizona4 papers (2016–2022)William T. Curry · Political Research Associates4 papers (2014–2015)S. Keith Anderson · Southwestern Medical Center4 papers (2016–2022)Paul D. Brown · Radiation Oncology Associates4 papers (2016–2022)Sepideh Amin‐Hanjani · University Hospitals of Cleveland4 papers (2012–2020)Karla V. Ballman · Mayo Clinic4 papers (2016–2022) · 4 papers (2016–2022)Elana Farace · Pennsylvania State University4 papers (2016–2022)Jay S. Loeffler · Massachusetts General Hospital3 papers (2013–2015)David Roberge · Centre Hospitalier de l’Université de Montréal3 papers (2016–2022)Deepak Khuntia · Siemens Healthcare (United States)3 papers (2016–2022)Anthony Whitton · McMaster University3 papers (2016–2022)Pamela S. Jones · Massachusetts General Hospital3 papers (2014–2019)Ian F. Parney · Wake Forest University3 papers (2016–2022)Helen A. Shih · Harvard University3 papers (2014–2015)Jeffrey Greenspoon · Novartis (Canada)3 papers (2016–2022)Scott R. Plotkin · Harvard University3 papers (2012–2023)Zoher Ghogawala · Tufts University3 papers (2016–2021)